Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9097753 | 0.89 | DRD2 (0.55) | ACHEHTR7OPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL9097011 | 0.88 | DRD2 (0.54) | ACHEHTR7OPRM1OPRK1OPRL1 | |
| SCHEMBL9094898 | 0.88 | DRD2 (0.56) | ACHEHTR7OPRM1OPRK1OPRL1 | |
| SCHEMBL9097303 | 0.84 | ACHE (0.64) | ACHEOPRM1OPRK1OPRL1BCHE | |
| SCHEMBL12013902 | 0.83 | ACHE (0.75) | ACHEHTR7OPRM1OPRK1OPRL1 | |
| SCHEMBL6281445 | 0.82 | ACHE (0.58) | ACHE | |
| SCHEMBL9096175 | 0.81 | ACHE (0.67) | ACHE | |
| SCHEMBL27379861 | 0.81 | HTR7 (0.49) | HTR7 | |
| SCHEMBL9096623 | 0.79 | DRD4 (0.51) | HTR7 | |
| SCHEMBL14601865 | 0.76 | CHRM2 (0.71) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906090-B1 | Compositions and methods for treating mycobacterial diseases | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | claimed |
| EP-1058548-B1 | THE USE OF ISATIN AND OXINDOLE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF MYCOBACTERIAL DISEASE | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | claimed |
| EP-1058548-A1 | NEW USE | AstraZeneca AB (SE) | 2000-12-13 | — | — | EP | claimed |
| WO-1999044608-A1 | NEW USE | ASTRAZENECA AB (SE) | 1999-09-10 | — | — | WO | claimed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-6906090-B1 | Compositions and methods for treating mycobacterial diseases | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1058548-B1 | THE USE OF ISATIN AND OXINDOLE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF MYCOBACTERIAL DISEASE | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-1058548-A1 | NEW USE | AstraZeneca AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999044608-A1 | NEW USE | ASTRAZENECA AB (SE) | 1999-09-10 | — | — | WO | disclosed |
| US-5585378-A | Composition containing an oxoindole compound | AKTIEBOLAGET ASTRA (SE) | 1996-12-17 | — | — | US | disclosed |
| CN-1079464-A | Treatment comprises the preparation method of the valuable indolone of illness of cholinergic function reduction and the derivative of indole dione | ASTRA AB (SE) | 1993-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | ACHE 1/4885HTR7 1697/4885OPRM1 1053/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885HTR7 1962/4885OPRM1 974/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | ACHE 1/4885HTR7 2877/4885OPRM1 1269/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885HTR7 2102/4885OPRM1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.